Polymorphisms of the Human Platelet Antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the Platelet Receptors for Fibrinogen (GPIIb/IIIa), von Willebrand Factor (GPIb/IX), and Collagen (GPIa/IIa) Are Not Correlated With an Increased Risk for Stroke
- 1 July 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 28 (7) , 1392-1395
- https://doi.org/10.1161/01.str.28.7.1392
Abstract
Background and Purpose A recent study has described a high incidence of the human platelet antigen (HPA)-1b alloantigen in patients with myocardial infarction. We investigated the distribution of gene polymorphisms of platelet glycoproteins (GPs) in patients with cerebrovascular disease (CVD) and stroke. The polymorphic systems we have studied are HPA-1 and HPA-3 on the fibrinogen receptor (GPIIb/IIIa), HPA-2 on the von Willebrand factor receptor (GPIb/IX), and HPA-5 on one of the platelet collagen receptors (GPIa/IIa). Methods DNA was isolated from peripheral blood collected from 218 consecutive stroke patients, 165 neurological inpatients without signs of CVD, and 321 healthy blood donors. The genotypes of HPA-1, HPA-2, HPA-3, and HPA-5 were determined by sequence specific primer polymerase chain reactions. Results The calculated allele frequencies were as follows: for CVD patients, HPA-1a/b 0.81/0.19, HPA-2a/b 0.91/0.09, HPA-3a/b 0.61/0.39, and HPA-5a/b 0.92/0.08; for inpatients, HPA-1a/b 0.83/0.17, HPA-2a/b 0.91/0.09, HPA-3a/b 0.62/0.38, and HPA-5a/b 0.93/0.07; and for blood donors, HPA-1a/b 0.85/0.15, HPA-2a/b 0.94/0.06, HPA-3a/b 0.60/0.40, and HPA-5a/b 0.92/0.08. There were no statistically significant differences for the analyzed HPA polymorphism frequencies either between the CVD patients and the non-CVD inpatients or the CVD patients and blood donors. However, the HPA-1b genotype was slightly more frequent in patients (CVD and non-CVD) than in the healthy blood donors. Conclusions Our results indicate that the HPA-1, HPA-2, HPA-3, and HPA-5 polymorphisms are not associated with an increased risk for stroke.Keywords
This publication has 17 references indexed in Scilit:
- Platelet Glycoprotein IIIaPlAPolymorphism and Myocardial InfarctionNew England Journal of Medicine, 1996
- Frequency and functional relevance of genetic threonine145/methionine145 dimorphism in platelet glycoprotein Ibα in an Italian populationTransfusion, 1996
- Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation‐based typingTransfusion, 1996
- A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary ThrombosisNew England Journal of Medicine, 1996
- A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1 A1 from Pl A2Tissue Antigens, 1995
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- The human platelet alloantigens Br(a) and Brb are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit alpha 2).Journal of Clinical Investigation, 1993
- Development of a monoclonal antibody capable of differentiating platelet PLA1/PLA1, PLA1/PLA2and PLA2/PLA2genotypesBritish Journal of Haematology, 1992
- NH2-terminal globular domain of human platelet glycoprotein Ib alpha has a methionine 145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens.Journal of Clinical Investigation, 1992
- The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.Journal of Clinical Investigation, 1989